At the American Neurological Association (ANA) Annual Meeting, Dr. Timothy Miller presented VALOR study of Tofersen Phase 3 Drug Results and Use with ALS. Tofersen is an antisense drug being evaluated for the potential treatment of SOD1-ALS. For more information and to learn about Tofersen Phase 3 Drug Results please see links below.
Biogen News Release; October 17, 2021
ANA (American Neurological Association)
Slide Presentation by Tim Miller
October 17-19, 2021